~~<i id='7B8425AF27'><strike id='7B8425AF27'><tt id='7B8425AF27'><pre id='7B8425AF27'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

entertainment

author：fashion 2025-10-06 07:55:02 - browse：258

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： What is microchimerism and how does it affect maternal health?

entertainment

focus

Wikipedia

entertainment

knowledge

AdobeTherearetimeswhenanewmedicaltechnologyisthrustintothepublicspotlightbecauseitseemslikeitmightso

WSS

Gene therapy’s promise and the high cost of hope

The health care issue Democrats can’t solve: hospital reform

Prime Medicine says its gene editing passes test in monkeys

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

European officials brace for rough respiratory virus season

DeepMind touts AlphaFold's new skills as protein folding AI models face off

explore

entertainment

entertainment

BioMarin wins approval for gene therapy to treat hemophilia A

European officials brace for rough respiratory virus season

State Dept. review finds Biden bears some blame for Afghanistan failures

Life sciences investors close nearly $6 billion in new funds

Guidelines to prevent youth baseball injuries need more muscle

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Psychedelics group wrestles with new pharma identity

Life sciences investors close nearly $6 billion in new funds

Bright Health sells Medicare Advantage business to Molina

Will an HIV vaccine ever be a reality?

focus

DeepMind touts AlphaFold's new skills as protein folding AI models face off

After Sarepta trial failure, Duchenne families brace for more debate

Travis Kelce and the trap of celebrity vaccine endorsements

The Karikó problem: Lessons for funding basic research

What will Novo Nordisk's VC do with its influx of cash?

Medicare innovation center doesn’t save money, experts say

Wikipedia

entertainment

knowledge

knowledge